Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Globe Life Inc. (NYSE:GL ) Q4 2024 Earnings Conference Call February 6, 2025 11:00 AM ET Company Participants Stephen Mota - Senior Director, Investor Relations Frank Svoboda - Co-Chief Executive Officer Matt Darden - Co-Chief Executive Officer Tom Kalmbach - Chief Financial Officer Conference Call Participants Jimmy Bhullar - JPMorgan Jack Matten - BMO Capital Markets Elyse Greenspan - Wells Fargo Wilma Burdis - Raymond James John Barnidge - Piper Sandler Wes Carmichael - Autonomous Research Andrew Kligerman - TD Securities Suneet Kamath - Jefferies Tom Gallagher - Evercore Operator Welcome to the Globe Life Fourth Quarter 2024 Earnings Release Conference Call. My name is Alan and I'll be your coordinator for today's event.
GL's Q4 results reflect a rise in premium at both the life and health segments, improved net sales and higher investment income, offset by higher expenses.
While the top- and bottom-line numbers for Globe Life (GL) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Globe Life (GL) came out with quarterly earnings of $3.14 per share, beating the Zacks Consensus Estimate of $3.10 per share. This compares to earnings of $2.80 per share a year ago.
Life and supplemental health insurance firm Globe Life reported an increase in fourth-quarter profit on Wednesday, driven by stronger underwriting performance and higher income from investments.
Globe Life Inc.'s 4.250% Junior Subordinated Debentures GL-D offer a compelling investment with a 7.24% Yield to Maturity and a BBB+ credit rating. Despite a short report-induced price drop in April 2024, Globe Life's stock has recovered, reaffirming investor's confidence in the stability of the company. GL-D is undervalued compared to Globe Life's OTC bonds and offers the highest yield to maturity among similar baby bonds in the sector.
Globe Life demonstrates steady EPS growth due to disciplined underwriting and cost efficiency. The company targets lower to middle-income families, maintaining stable annualized premiums and high underwriting margins. Globe Life's strong liquidity, high RBC ratio, and quality investment portfolio bolster its financial health.
NEW YORK CITY, NY / ACCESSWIRE / January 14, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Globe Life Inc. ("Globe Life" or "the Company") (NYSE:GL). Investors who purchased Globe Life securities prior to May 8, 2019, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/GL.
NEW YORK CITY, NY / ACCESSWIRE / January 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Globe Life Inc. ("Globe Life" or "the Company") (NYSE:GL). Investors who purchased Globe Life securities prior to May 8, 2019, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/GL.
NEW YORK CITY, NY / ACCESSWIRE / January 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Globe Life Inc. ("Globe Life" or "the Company") (NYSE:GL). Investors who purchased Globe Life securities prior to May 8, 2019, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/GL.
GL stock rallies on premium growth, higher invested assets, favorable return on capital and financial flexibility as well as effective capital deployment.